From Financial Modeling Prep: 2025-05-13 16:00:00

AnaptysBio, Deciphera Pharmaceuticals, and other biotech companies face challenges in capital efficiency, with negative ROICs indicating poor returns on invested capital. CytomX Therapeutics stands out with a positive ROIC of 66.72%, showcasing effective capital utilization and superior performance in the industry. Investors may find CytomX’s approach more appealing for potential investment opportunities.



Read more at Financial Modeling Prep:: AnaptysBio, Inc. (NASDAQ:ANAB) and Its Competitive Landscape in Biotechnology